|
Response parametera
|
n = 55
|
|---|
|
ORR, %
|
29.1
|
|
DCR, %b
|
60.0
|
|
Confirmed BOR, n (%)
|
|
CR
|
6 (10.9)
|
|
PR
|
10 (18.2)
|
|
SD
|
17 (30.9)
|
|
PDc
|
22 (40.0)
|
|
Duration of treatment for patients with responsed
|
|
Median (range), months
|
9.7 (3.5–41.7)
|
- BOR best overall response, CR complete response, DCR disease control rate, EAP expanded access program, MCC Merkel cell carcinoma, PD progressive disease, PR partial response, SD stable disease
- aResponse was reported according to treating-physician assessment of follow-up scans at the time of resupply
- bAmong patients treated for a minimum of 3 months with available data
- cPatients with PD or adverse events that required treatment discontinuation within the first 90 days were never resupplied and did not have a follow-up response evaluation; thus, these values may be underreported
- dDuration of avelumab treatment/drug supply is reported as a surrogate for duration of response or clinical benefit
